SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine “storm” and risk factor for damage of hematopoietic stem cells

The scientific community faces an unexpected and urgent challenge related to the SARS-CoV-2 pandemic and is investigating the role of receptors involved in entry of this virus into cells as well as pathomechanisms leading to a cytokine “storm,” which in many cases ends in severe acute respiratory syndrome, fulminant myocarditis and kidney injury. An important question is if it may also damage hematopoietic stem progenitor cells?

[1]  T. Kanneganti,et al.  Recent advances in inflammasome biology. , 2018, Current opinion in immunology.

[2]  Y. Meng,et al.  Mir-21 Mediates the Inhibitory Effect of Ang (1–7) on AngII-induced NLRP3 Inflammasome Activation by Targeting Spry1 in lung fibroblasts , 2017, Scientific Reports.

[3]  A. Pinar,et al.  Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis. , 2020, Pharmacology & therapeutics.

[4]  L. Pagano,et al.  Frequently asked questions regarding SARS-CoV-2 in cancer patients—recommendations for clinicians caring for patients with malignant diseases , 2020, Leukemia.

[5]  T. Park,et al.  A role for the renin-angiotensin system in hematopoiesis , 2009, Haematologica.

[6]  Zhanjun Jia,et al.  Angiotensin II Stimulates the NLRP3 Inflammasome to Induce Podocyte Injury and Mitochondrial Dysfunction , 2018, Kidney Diseases.

[7]  Elias T. Zambidis,et al.  Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells. , 2008, Blood.

[8]  M. Ratajczak,et al.  The Nlrp3 inflammasome as a “rising star” in studies of normal and malignant hematopoiesis , 2020, Leukemia.

[9]  David Berlin,et al.  Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases , 2020, Translational Research.

[10]  R. Gale,et al.  COVID-19 in persons with haematological cancers , 2020, Leukemia.

[11]  K. Rodgers,et al.  Effect of angiotensin II and angiotensin(1–7) on hematopoietic recovery after intravenous chemotherapy , 2003, Cancer Chemotherapy and Pharmacology.

[12]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[13]  W. Xu,et al.  Retraction Note to: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion , 2020, Cellular & Molecular Immunology.

[14]  Marc A Pfeffer,et al.  Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 , 2020, The New England journal of medicine.

[15]  F. Violi,et al.  Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge , 2020, Thrombosis and Haemostasis.